Antiviral Use Among Infants Diagnosed With Congenital Cytomegalovirus (cCMV) in the United States: A Retrospective Analysis of Administrative Claims Data, 2007 to 2024.
Real-world data on antiviral treatment for congenital cytomegalovirus reveals how practice patterns have evolved with improved neonatal awareness.
This retrospective administrative claims analysis describes antiviral treatment patterns for congenital cytomegalovirus infection in US infants from 2007-2024, providing population-level real-world evidence on treatment uptake for this rare but potentially devastating neonatal infection. The study fills a gap in understanding treatment practice evolution following expanded cCMV awareness and neonatal screening initiatives over the past decade.
What the study was
- Study design
- Retrospective claims analysis
- Population
- US infants diagnosed with congenital cytomegalovirus (cCMV), 2007-2024; administrative claims database
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Clinical Therapeutics
Why it surfaced
Rare neonatal infection (cCMV) real-world treatment patterns from large US claims dataset 2007-2024; informs understanding of access and practice for an underdiagnosed rare disease with neurodevelopmental consequences.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.